Non-24-hour sleep-wake disorder successfully treated with the combination of ramelteon and suvorexant in a case of autism spectrum disorder

Neuropsychopharmacol Rep. 2020 Dec;40(4):383-387. doi: 10.1002/npr2.12142. Epub 2020 Sep 29.

Abstract

Introduction: Non-24-hour sleep-wake disorder (N24SWD) is often observed in the visually impaired and those who isolate indoors. Melatonin receptor agonists may be used for treatment, but there is currently no evidence that they are effective in patients without visual impairment.

Case: We report a case of a 23-year-old woman who withdrew from her social life owing to autism spectrum disorder and experienced an unusual sleep rhythm. She presented with N24SWD. The N24SWD cycle averaged 25.6 days but was extended to 42 days using ramelteon. However, this was not enough. We prescribed the addition of suvorexant and the sleep cycle returned to normal.

Conclusion: N24SWD is a disease that seriously impairs social life and productivity. We propose a possible treatment strategy for N24SWD using ramelteon and suvorexant.

Keywords: autism; melatonin; non-24 hour sleep-wake disorder; ramelteon; suvorexant.

Publication types

  • Case Reports

MeSH terms

  • Autism Spectrum Disorder / complications
  • Autism Spectrum Disorder / diagnosis
  • Autism Spectrum Disorder / drug therapy*
  • Azepines / administration & dosage*
  • Drug Therapy, Combination
  • Female
  • Humans
  • Indenes / administration & dosage*
  • Sleep Aids, Pharmaceutical / administration & dosage*
  • Sleep Disorders, Circadian Rhythm / complications
  • Sleep Disorders, Circadian Rhythm / diagnosis
  • Sleep Disorders, Circadian Rhythm / drug therapy*
  • Treatment Outcome
  • Triazoles / administration & dosage*
  • Young Adult

Substances

  • Azepines
  • Indenes
  • Sleep Aids, Pharmaceutical
  • Triazoles
  • suvorexant
  • ramelteon